Chagas Disease

Table of Contents

1. Overview
2. Epidemiology
3. Transmission Routes
4. Acute Phase
5. Chronic Indeterminate Form
6. Chronic Cardiac Form
7. Chronic Digestive Form
8. Diagnosis
9. Treatment
10. Prevention
11. References
12. PubMed Searches
13. Connections
14. Featured Videos

Overview

Chagas disease (American trypanosomiasis) is caused by Trypanosoma cruzi, an intracellular protozoan flagellate. The disease was named after Carlos Chagas, who discovered it in 1909 — making it one of the few diseases in history named after the same scientist who identified both the causative pathogen and its insect vector. An estimated 6 to 7 million people are infected worldwide, with the burden concentrated in Latin America, where Chagas disease is the leading cause of non-ischemic cardiomyopathy in the region.

The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease (NTD). Its clinical course is defined by two distinct phases: an acute phase lasting weeks to months, followed by a chronic phase that can persist for decades. While 60 to 70 percent of chronically infected individuals remain in an asymptomatic "indeterminate form," approximately 30 to 40 percent eventually develop serious organ damage — primarily affecting the heart and gastrointestinal tract. A unique and epidemiologically important feature of Chagas disease is its acquisition through multiple transmission routes beyond the classic insect bite, including blood transfusion, organ transplantation, congenital transfer, and oral ingestion of contaminated food.

Back to Table of Contents

Epidemiology

Chagas disease is endemic in 21 Latin American countries. Brazil, Argentina, and Bolivia carry the highest total burden, with Bolivia recording the world's highest national prevalence — estimated at approximately 6 percent of the population. Historically a disease of rural poverty, urban migration has progressively shifted the distribution toward cities, and the disease now causes significant morbidity in urban Latin American centers.

Globalization has spread Chagas beyond its traditional geographic boundaries. An estimated 300,000 infected individuals live in the United States, the vast majority undiagnosed; approximately 80,000 are estimated to reside in Europe, with additional populations in Australia and Japan. These figures reflect Latin American diaspora communities and underscore the importance of screening programs outside endemic areas.

The primary insect vector is the triatomine bug — Triatoma infestans is the dominant species in the Southern Cone countries of South America, Triatoma dimidiata in Central America, and Rhodnius prolixus in Venezuela and Colombia. Triatomine bugs thrive in the cracks and crevices of adobe, mud, and thatch structures characteristic of rural poverty housing. Climate change is expanding the thermal range of triatomine species northward into the southern United States, raising concern about wider vector-borne transmission. In urban and non-endemic settings, non-vector routes — blood transfusion, organ transplantation, and congenital transmission — have become proportionally more important.

Back to Table of Contents

Transmission Routes

Chagas disease is transmitted by more routes than most parasitic infections, a fact with important implications for urban and non-endemic settings.

Vector-borne transmission remains the primary route in rural endemic areas. Triatomine bugs — known colloquially as "kissing bugs," "vinchuca" (Argentina/Chile), or "barbeiro" (Brazil) — are obligate nocturnal blood feeders. They preferentially bite the face and lips of sleeping hosts. A critical distinction from malaria and leishmaniasis: Trypanosoma cruzi is NOT transmitted through the bug's saliva but through its feces. The triatomine defecates while or immediately after feeding; the host then inadvertently rubs infected feces into the bite wound or onto a mucous membrane such as the conjunctiva or mouth.

Blood transfusion became a major route as rural populations urbanized. Most Latin American countries now mandate donor screening for Chagas, and the United States and many European nations have implemented testing for donors born in or who lived in endemic areas.

Organ and tissue transplantation carries risk when donors originate from endemic regions. Recipients become infected when they receive an organ harboring dormant parasites, and the required post-transplant immunosuppression can trigger rapid disease progression.

Congenital transmission occurs in approximately 5 to 10 percent of infants born to infected mothers, making maternal Chagas an important cause of neonatal infection. Without screening, these infants go undiagnosed.

Oral transmission via ingestion of food or drink contaminated with triatomine feces or infected animal tissue has caused documented outbreaks in Brazil and other countries. Implicated vehicles include unpasteurized sugarcane juice, açaí palm juice, and guava juice. Orally acquired infection can produce unusually severe acute disease with higher parasitemia than vector-borne routes, likely because the gastrointestinal mucosa allows high-level inoculation.

Laboratory accidents from exposure to infected blood or cultures represent a rare but recognized occupational hazard.

Back to Table of Contents

Acute Phase

The acute phase begins within the first 4 to 8 weeks after infection and corresponds to the period of highest parasitemia — when trypomastigotes are freely circulating in the bloodstream. Despite this high parasite burden, more than 70 percent of acute cases are entirely asymptomatic or present only with nonspecific febrile illness indistinguishable from viral infection. The acute phase goes unrecognized in the vast majority of people who will later develop chronic disease.

When specific signs are present, they are highly characteristic:

• Romaña's sign — unilateral, painless periorbital edema (swelling of one eye) resulting from conjunctival inoculation with triatomine feces. When present, it is pathognomonic for acute Chagas disease, but it occurs in only approximately 50 percent of symptomatic acute cases. The swelling may persist for weeks.
• Chagoma — an indurated, erythematous skin lesion at the site of skin inoculation, accompanied by regional lymphadenopathy. The combination of a chagoma with regional adenopathy is analogous to the inoculation complex seen in other vector-borne infections.

Systemic features of the acute phase include fever, malaise, anorexia, hepatosplenomegaly, rash, and generalized lymphadenopathy. Serious complications occur in a minority of patients, primarily young children and immunocompromised individuals: acute myocarditis (manifesting as chest pain, palpitations, conduction abnormalities, and potentially life-threatening heart failure) and acute meningoencephalitis (most dangerous in infants under age 2, carrying high mortality). Oral transmission outbreaks are associated with unusually severe acute presentations due to higher inoculum.

Back to Table of Contents

Chronic Indeterminate Form

After the acute phase resolves — whether symptomatic or silent — the infection enters a chronic phase. Between 60 and 70 percent of chronically infected people enter a lifelong state termed the "indeterminate form": they are seropositive (antibody tests confirm infection) but have no symptoms, a normal 12-lead electrocardiogram (or only minor non-specific changes), a normal echocardiogram, and normal barium swallow and enema studies. Many maintain low-level parasitemia that can be detected by PCR even after decades of infection.

The indeterminate form is not "cured" — the parasite persists in cardiac and gastrointestinal tissue, evading immune clearance through intracellular residence and antigenic variation. The annual conversion rate to clinically apparent organ disease is approximately 2 to 5 percent per year, meaning that over a lifetime, a substantial proportion of indeterminate-form patients will eventually develop cardiac or digestive manifestations.

Clinically important considerations in indeterminate-form patients:

• Immunosuppression — from HIV infection, post-transplant immunosuppressive therapy, or chemotherapy — can trigger reactivation to severe acute disease, including CNS involvement (brain abscess or meningoencephalitis from T. cruzi)
• Evidence supports antiparasitic treatment even in asymptomatic indeterminate-form adults, as treatment is believed to slow progression to organ damage, though the BENEFIT trial (2015) showed no reduction in clinical events in patients with already-established cardiomyopathy
• Stress, intercurrent illness, and aging are thought to accelerate transition from indeterminate to determinate form

Back to Table of Contents

Chronic Cardiac Form

Chagasic cardiomyopathy develops in 20 to 30 percent of chronically infected individuals, typically 10 to 30 years after the initial infection. It is a dilated cardiomyopathy with several distinguishing features that differentiate it from other causes of dilated cardiomyopathy (DCM):

• Apical aneurysm — a thin-walled aneurysm of the left ventricular apex, caused by segmental fibrosis, is considered pathognomonic of Chagasic cardiomyopathy when found in the appropriate clinical context. This aneurysm is a nidus for thrombus formation.
• Right bundle branch block (RBBB) — often combined with left anterior fascicular block to form a bifascicular block pattern — is the electrocardiographic hallmark. RBBB in an asymptomatic patient from an endemic region should prompt serological testing for Chagas.
• Ventricular arrhythmias — sustained ventricular tachycardia and ventricular fibrillation are the leading cause of death in chronic Chagas disease, accounting for 50 to 65 percent of all deaths. Sudden cardiac death may occur even before overt heart failure develops.
• Biventricular dilation and systolic dysfunction — progressive reduction in ejection fraction with biventricular enlargement, leading to dyspnea, exercise intolerance, and peripheral edema.
• Thromboembolism — apical thrombus from the ventricular aneurysm can embolize to the brain (stroke) or pulmonary circulation (pulmonary embolism). Atrial fibrillation further increases thromboembolic risk.
• Sick sinus syndrome and complete heart block — conduction system fibrosis can produce symptomatic bradyarrhythmias requiring pacemaker implantation.

Cardiac magnetic resonance imaging (CMR) demonstrates a distinctive fibrosis pattern in Chagasic cardiomyopathy: late gadolinium enhancement is characteristically subepicardial and midmyocardial in the lateral and inferior walls — a pattern that differs from ischemic (subendocardial) and other inflammatory cardiomyopathies, aiding differential diagnosis.

Back to Table of Contents

Chronic Digestive Form

Approximately 10 to 15 percent of chronically infected individuals develop digestive manifestations of Chagas disease. The underlying mechanism is progressive destruction of the myenteric plexus (Auerbach's plexus) — the network of autonomic neurons embedded in the muscular wall of the gastrointestinal tract — by the chronic parasite-driven inflammatory process. Loss of these neurons disrupts normal peristaltic coordination, leading to the characteristic "mega" syndromes.

Megaesophagus produces dysphagia that initially affects solid foods and progresses to liquids, along with regurgitation, nocturnal aspiration, and progressive weight loss. The motor pattern resembles achalasia — failure of the lower esophageal sphincter to relax and absent or disorganized peristalsis. Chagasic megaesophagus is classified radiologically using the Rezende scale (grades I through IV) based on esophageal diameter and retention of contrast medium. Advanced megaesophagus carries significant risk of aspiration pneumonia. Treatment options progress from dietary modification (soft foods, upright positioning) and prokinetic agents for early disease, to endoscopic pneumatic dilation or Heller myotomy, to peroral endoscopic myotomy (POEM) for advanced cases.

Megacolon manifests as severe chronic constipation, prolonged colonic transit, fecal impaction, and potentially sigmoid volvulus — a surgical emergency in which the redundant, atonic sigmoid twists on its mesentery, causing obstruction and ischemia. Sigmoid resection with primary anastomosis is the definitive treatment for recurrent volvulus or complicated megacolon. Megaduodenum and megastomach occur less commonly. Cardiac and digestive forms can coexist in the same patient, and both may appear in the same household cluster.

Back to Table of Contents

Diagnosis

The diagnostic approach to Chagas disease differs fundamentally between the acute and chronic phases, reflecting the drastically different levels of circulating parasitemia in each.

Acute Phase Diagnosis

During acute infection, parasitemia is high and direct parasitological methods are sensitive:

• Fresh blood smear or buffy coat examination — direct microscopic visualization of motile trypomastigotes; rapid and inexpensive when parasitemia is high
• Giemsa-stained thin and thick blood smears — identifies trypomastigotes morphologically; the large kinetoplast at the posterior end distinguishes T. cruzi from T. brucei
• PCR — highly sensitive, now the preferred reference method for acute diagnosis; identifies parasite DNA even when parasitemia is below microscopic threshold
• Xenodiagnosis — allowing laboratory-reared uninfected triatomine bugs to feed on the patient, then examining their feces for trypomastigotes; historically considered the gold standard but impractical in modern settings

Chronic Phase Diagnosis

In chronic infection, parasitemia is low and intermittent, rendering direct parasitological methods unreliable. Serology is the standard diagnostic approach:

• Two serological tests using different antigens or platforms are required per WHO and Pan American Health Organization (PAHO) recommendations — both must be positive to confirm diagnosis; a single positive result is indeterminate and requires a third confirmatory test. Recommended combinations include ELISA plus immunofluorescence, ELISA plus immunoblot, or two ELISAs based on different antigens.
• PCR on peripheral blood — useful for monitoring antiparasitic treatment response and detecting reactivation in immunocompromised patients, but not sensitive enough for primary chronic-phase diagnosis due to intermittent parasitemia

Cardiac and Digestive Evaluation

• 12-lead ECG — right bundle branch block with or without left anterior fascicular block in a seropositive patient is highly suggestive of Chagasic cardiomyopathy
• Echocardiography — identifies apical aneurysm, regional wall motion abnormalities, biventricular dilation, and reduced ejection fraction
• Holter monitoring (24-hour ambulatory ECG) — detects paroxysmal ventricular arrhythmias that may not appear on a resting ECG
• Cardiac MRI — maps the distribution and extent of myocardial fibrosis with high precision; the subepicardial/midmyocardial lateral and inferior wall pattern is characteristic
• Barium swallow and barium enema — assess esophageal motor function and colonic caliber for digestive form; Rezende grading for megaesophagus

Back to Table of Contents

Treatment

Treatment of Chagas disease encompasses antiparasitic therapy to eliminate or suppress the parasite, and organ-specific management for cardiac and digestive complications.

Antiparasitic Treatment

Two drugs are available for antiparasitic treatment:

• Benznidazole (first-line globally) — 5 to 7 mg/kg/day in two divided doses for 60 days. The most widely used agent; most effective when given early (cure rates exceeding 80 percent in the acute phase vs. 20 to 80 percent in the chronic phase depending on duration of infection). Common side effects include dermatitis (the most frequent adverse effect, occurring in 20 to 30 percent of patients), peripheral neuropathy, and gastrointestinal symptoms.
• Nifurtimox (second-line) — 8 to 10 mg/kg/day in three to four divided doses for 60 to 90 days. Side effects are predominantly neurological (headache, insomnia, irritability, peripheral neuropathy) and gastrointestinal. Both drugs are contraindicated in pregnancy and in patients with severe liver or renal disease.

WHO recommends antiparasitic treatment for: all acute cases regardless of age; all chronically infected individuals under 18 years; all cases of reactivation in immunocompromised patients; all congenitally infected infants. For adults in the chronic indeterminate form, treatment is recommended based on evidence that it slows progression, even though the BENEFIT trial (2015, PMID 26323937) found no reduction in clinical cardiac events in patients with already-established cardiomyopathy.

Cardiac Management

• Antiarrhythmic therapy — amiodarone is the preferred agent for ventricular arrhythmias in Chagasic cardiomyopathy; standard antiarrhythmics may be less effective or proarrhythmic in this setting
• Implantable cardioverter-defibrillator (ICD) — indicated for high-risk patients with sustained ventricular tachycardia, ejection fraction below 35 percent, or unexplained syncope
• Pacemaker or cardiac resynchronization therapy (CRT) — for symptomatic bradycardia from sick sinus syndrome or high-degree atrioventricular block
• Anticoagulation — for apical thrombus, atrial fibrillation, or severely reduced ejection fraction to prevent thromboembolic stroke
• Heart failure therapy — standard guideline-directed medical therapy (ACE inhibitors or ARBs, beta-blockers, mineralocorticoid receptor antagonists, diuretics) for systolic dysfunction
• Heart transplantation — an option for end-stage Chagasic cardiomyopathy; outcomes are comparable to transplant for other cardiomyopathies, but post-transplant immunosuppression can trigger parasite reactivation. Long-term antiparasitic prophylaxis (typically benznidazole) is required after transplant.

Back to Table of Contents

Prevention

No licensed vaccine for human Chagas disease currently exists. Prevention relies on a combination of vector control, blood safety measures, screening programs, and community education.

Vector control has been the most impactful intervention at the population level. Indoor residual spraying with pyrethroid insecticides targets triatomine bugs in their hiding places within wall cracks and thatched ceilings. The Southern Cone Initiative, launched in 1991 by Argentina, Bolivia, Brazil, Chile, Paraguay, and Uruguay, achieved dramatic reductions in T. infestans density. Uruguay, Chile, and Brazil have been officially certified as having interrupted vector-borne transmission. Improved housing — replacing mud and thatch walls with plastered cement walls and metal roofing — removes triatomine habitat and is the most durable long-term solution.

Blood supply screening is now mandatory in most Latin American countries. In the United States, blood donations have been tested for T. cruzi antibodies since 2007. The European Union and other non-endemic countries test donors from or with exposure to endemic regions.

Organ transplant screening — serological testing of both donors and recipients from endemic-area backgrounds — is recommended to identify recipients who require antiparasitic prophylaxis or close monitoring post-transplant.

Congenital Chagas prevention — screening pregnant women from endemic areas and testing their neonates at 6 to 9 months (when maternal antibodies have cleared) allows early identification and treatment of infected infants, who have excellent cure rates when treated early.

Oral transmission prevention — pasteurization and proper hygiene in production of fruit juices (açaí, sugarcane, guava) in endemic areas prevents outbreak-associated oral Chagas.

Traveler guidance — travelers to rural endemic areas should sleep in insect-proof accommodations, avoid thatch and adobe structures, use permethrin-treated bed nets, apply DEET repellent, and avoid homemade fruit juices of uncertain origin. No chemoprophylaxis is available.

Back to Table of Contents

References

1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–1402. DOI: 10.1016/S0140-6736(10)60061-X — PMID 20399979
2. Bern C. Chagas' Disease. N Engl J Med. 2015;373:456–466. DOI: 10.1056/NEJMra1410150 — PMID 26222561
3. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115:1109–1123. DOI: 10.1161/CIRCULATIONAHA.106.624296 — PMID 17339569
4. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med. 2015;373:1295–1306. DOI: 10.1056/NEJMoa1507574 — PMID 26323937
5. Coura JR, Viñas PA. Chagas disease: a new worldwide challenge. Nature. 2010;465:S6–S7. DOI: 10.1038/nature09221 — PMID 20530919
6. Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL. Chagas disease: an overview of clinical and epidemiological aspects. J Am Coll Cardiol. 2013;62:767–776. DOI: 10.1016/j.jacc.2013.05.046 — PMID 23770163
7. Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis. 2011;5:e931. DOI: 10.1371/journal.pntd.0000931 — PMID 21264349
8. Pinazo MJ, Espinosa G, Cortes-Lletget C, et al. Importance of follow-up in congenital and adult Chagas disease. Ann N Y Acad Sci. 2009;1156:281–297. DOI: 10.1111/j.1749-6632.2009.04351.x — PMID 19338512
9. Bestetti RB, Cardinalli-Neto A. Sudden cardiac death in Chagas' heart disease in the contemporary era. Int J Cardiol. 2008;131:9–17. DOI: 10.1016/j.ijcard.2008.04.003 — PMID 18501446
10. Pereira Nunes MC, Kreuser LJ, Ribeiro AL. Heart failure due to Chagas disease: time to implement clinical practice guidelines. JACC Heart Fail. 2015;3:634–638. DOI: 10.1016/j.jchf.2015.07.001 — PMID 26248991
11. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Am J Trop Med Hyg. 2009;80:26–33. DOI: 10.4269/ajtmh.2009.80.26 — PMID 19141834
12. Bonney KM. Chagas disease in the 21st century: a public health success or an emerging threat? Parasite. 2014;21:11. DOI: 10.1051/parasite/2014012 — PMID 24594866

Back to Table of Contents

PubMed Searches

The following PubMed search links provide access to the latest peer-reviewed research on Chagas disease:

1. Chagas disease cardiomyopathy treatment
2. Trypanosoma cruzi acute infection diagnosis
3. Benznidazole and nifurtimox for Chagas disease
4. Chagas disease sudden cardiac death and ventricular arrhythmia
5. Congenital Chagas disease screening
6. Chagas megaesophagus and megacolon
7. Triatomine vector control for Chagas disease
8. Chagas disease indeterminate form and progression

Back to Table of Contents

Connections

• Infectious Disease
• Malaria
• Leishmaniasis
• Schistosomiasis
• HIV/AIDS
• Heart Failure
• Stroke
• Lab Tests

Back to Table of Contents